Home›Stock Screener›Piramal Pharma›Financial Statements

Piramal Pharma Complete Financial Statements

6 Years of Data
2026 - 2021

In FY2026, Piramal Pharma (PPLPHARMA) reported revenue ₹2,811 Cr, net profit ₹-9 Cr and EPS ₹-0.07, with a net profit margin of -0.3% and ROE of -0.1%. Full financial statements from FY2021 to FY2026 (6 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. Explore PPLPHARMA investment value to estimate fundamental worth using multiple valuation models.

Complete Financial Data Export

Profitability Ratios

Net Profit Margin -0.32% 2026 data
EBITDA Margin 12.24% 2026 data
Operating Margin 10.00% 2026 data
Return on Assets -0.05% 2026 data
Return on Equity -0.11% 2026 data

Balance Sheet Ratios

Current Ratio 1.43 2026 data
Equity Ratio 45.44% 2026 data
Asset Turnover 0.16 2026 data

PPLPHARMA Revenue, Net Profit & EBITDA — Year-on-Year Growth

PPLPHARMA YoY (Mar 2025 vs Mar 2026) — revenue 0.0%, net profit -105.8%, EBITDA -44.4%, expenses +12.5%. Review Piramal Pharma P/E valuation to evaluate earnings-based valuation against sector peers.

Revenue Growth
0.0%
Year-over-Year
Net Profit Growth
-105.8%
Year-over-Year
EBITDA Growth
-44.4%
Year-over-Year
Expense Growth
+12.5%
Year-over-Year
Assets Growth
+14.6%
Year-over-Year
Equity Growth
+0.5%
Year-over-Year
Operating Cash Flow Growth
-11.2%
Year-over-Year
Investing Cash Flow Growth
-17.3%
Year-over-Year
Financing Cash Flow Growth
-4.5%
Year-over-Year

PPLPHARMA Income Statement — Revenue, EBITDA & Net Profit

Piramal Pharma revenue ₹2,811 Cr, EBITDA ₹344 Cr, net profit ₹-9 Cr, EPS ₹-0.07 (2026) — net profit margin -0.3%. For live price, earnings ratios and company overview, see PPLPHARMA share price screener.

Periods ₹ Crores
Particulars Mar 2026 Sept 2025 Mar 2025 Jun 2025 Dec 2025 Sept 2024 Mar 2024 Jun 2024 Dec 2024 Sept 2023 Mar 2023 Jun 2023 Dec 2023 Sept 2022 Mar 2022 Jun 2022 Dec 2022 Sept 2021 Jun 2021 Dec 2021
Revenue 2,811 2,124 2,812 2,031 2,193 2,320 2,591 1,993 2,233 1,980 2,196 1,802 2,034 1,777 2,229 1,574 1,814 1,612 1,345 1,709
Expenses 2,467 1,885 2,193 1,827 1,985 1,900 2,053 1,747 1,867 1,646 1,812 1,617 1,723 1,554 1,733 1,465 1,629 1,381 1,197 1,314
EBITDA 344 239 619 204 208 420 538 246 367 334 384 185 312 223 495 109 185 231 148 395
Operating Profit Margin % 10.00% 8.00% 20.00% 6.00% 7.00% 15.00% 20.00% 10.00% 15.00% 14.00% 16.00% 8.00% 12.00% 10.00% 19.00% 1.00% 5.00% 12.00% 9.00% 15.00%
Depreciation 218 203 243 197 213 192 196 185 197 185 184 174 186 166 165 162 164 138 136 147
Interest 83 82 104 86 89 108 114 107 103 110 104 119 106 83 57 62 95 49 42 50
Profit Before Tax 43 -46 273 -79 -94 120 228 -45 67 40 95 -107 19 -26 273 -115 -74 44 -30 198
Tax 52 53 119 3 42 98 126 44 63 35 45 -9 9 11 69 -6 17 7 -2 35
Net Profit -9 -99 154 -82 -136 23 101 -89 4 5 50 -99 10 -37 204 -109 -90 37 -28 163
Earnings Per Share (₹) -0.07 -0.75 1.16 -0.62 -1.03 0.17 0.77 -0.67 0.03 0.04 0.42 -0.83 0.08 -0.31 1.72 -0.92 -0.76 0.31 0.00 1.38

PPLPHARMA Balance Sheet — Assets, Liabilities & Shareholders' Equity

PPLPHARMA total assets ₹17,965 Cr, total equity ₹8,163 Cr, total liabilities ₹ Cr (2026) — ROE -0.1%.

Years Annual Data ₹ Crores
Particulars 2026 2025 2024 2023 2022 2021
ASSETS
Total Assets 17,965 15,678 15,312 14,523 12,797 10,900
Current Assets 7,192 5,797 5,465 4,836 4,067 3,649
Fixed Assets 8,526 8,133 7,990 7,469 6,879 6,106
Capital Work in Progress 799 977 1,116 1,419 1,172 627
Investments 3,064 291 385 639 267 123
Other Assets 0 6,277 5,821 4,996 4,478 4,045
LIABILITIES
Total Liabilities
Current Liabilities 5,044 3,786 3,031 3,906 3,067 2,805
Non-Current Liabilities
SHAREHOLDERS' EQUITY
Total Equity 8,163 8,126 7,911 6,774 6,697 5,605
Share Capital 1,327 1,324 1,323 1,193 1,186 995
Reserves & Surplus 6,836 6,801 6,588 5,580 5,511 4,610

PPLPHARMA Cash Flow Statement — Operating, Investing & Financing

Piramal Pharma operating cash flow ₹892 Cr, investing ₹-488 Cr, financing ₹-441 Cr, net cash flow ₹-37 Cr (2025).

Periods ₹ Crores
Particulars March 2025 March 2024 March 2023 March 2022 March 2021
Operating Activities 892 1,005 484 766 598
Investing Activities -488 -416 -1,334 -1,737 -4,464
Financing Activities -441 -422 818 794 3,977
Net Cash Flow -37 166 -32 -177 110